Advances in respiratory virus therapeutics - A meeting report from the 6th for isirv Antiviral Group conference

被引：118

作者：

Beigel, John H. ^{[1
]}

Nam, Hannah H. ^{[2
]}

Adams, Peter L. ^{[3
]}

Krafft, Amy ^{[1
]}

Ince, William L. ^{[4
]}

El-Kamary, Sutler S. ^{[4
]}

Sims, Amy C. ^{[5
]}

机构：

[1] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[3] US Dept HHS, BARDA, Off Assistant Secretary Preparedness & Response A, Washington, DC 20201 USA

[4] US FDA, Div Antiviral Prod, Off Antimicrobial Prod, Off New Drugs,Ctr Drug Evaluat & Res, Silver Spring, MD USA

[5] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA

来源：

ANTIVIRAL RESEARCH | 2019年 / 167卷

关键词：

Influenza; Respiratory syncytial virus; Coronavirus; Antiviral therapy; Host-directed therapeutics; HUMAN MONOCLONAL-ANTIBODY; MERS-COV INFECTION; SYNCYTIAL VIRUS; SYNDROME CORONAVIRUS; INFLUENZA-A; DOUBLE-BLIND; HIGH-RISK; NEURAMINIDASE INHIBITORS; UNCOMPLICATED INFLUENZA; VIRAL-INFECTIONS;

D O I：

10.1016/j.antiviral.2019.04.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, November 13-15, 2018. The three-day program was focused on therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses. Updates were presented on several influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies including nitazoxanide, eritoran, and diltiazem. Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development. The aim of this report is to provide a summary of the presentations given at this meeting.

引用

页码：45 / 67

页数：23

共 145 条

[21] Arbidol as a broad-spectrum antiviral: An update [J].

Blaising, Julie ;

Polyak, Stephen J. ;

Pecheur, Eve-Isabelle .

ANTIVIRAL RESEARCH, 2014, 107 :84-94

[22] Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes [J].

Borghardt, Jens Markus ;

Kloft, Charlotte ;

Sharma, Ashish .

CANADIAN RESPIRATORY JOURNAL, 2018, 2018

[23] Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern [J].

Bright, RA ;

Medina, MJ ;

Xu, XY ;

Perez-Oronoz, G ;

Wallis, TR ;

Davis, XHM ;

Povinelli, L ;

Cox, NJ ;

Klimov, AI .

LANCET, 2005, 366 (9492) :1175-1181

[24] Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit [J].

Byrn, Randal A. ;

Jones, Steven M. ;

Bennett, Hamilton B. ;

Bral, Chris ;

Clark, Michael P. ;

Jacobs, Marc D. ;

Kwong, Ann D. ;

Ledeboer, Mark W. ;

Leeman, Joshua R. ;

McNeil, Colleen F. ;

Murcko, Mark A. ;

Nezami, Azin ;

Perola, Emanuele ;

Rijnbrand, Rene ;

Saxena, Kumkum ;

Tsai, Alice W. ;

Zhou, Yi ;

Charifson, Paul S. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (03) :1574-1587

[25] Short period incidence sTudy of severe acute respiratory infection (SPRINT-SARI) initial data from a global observational study to better describe SARI epidemiology in critically ill patients [J].

Carson, G. L. ;

Castle, L. ;

George, M. ;

Horby, P. ;

Longuere, K. -S. ;

Merson, L. ;

Murthy, S. ;

O'neill, G. ;

Pardinaz-Solis, R. ;

Webb, S. .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 53 :101-101

[26] Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus [J].

Chan, Jasper F. W. ;

Chan, Kwok-Hung ;

Kao, Richard Y. T. ;

To, Kelvin K. W. ;

Zheng, Bo-Jian ;

Li, Clara P. Y. ;

Li, Patrick T. W. ;

Dai, Jun ;

Mok, Florence K. Y. ;

Chen, Honglin ;

Hayden, Frederick G. ;

Yuen, Kwok-Yung .

JOURNAL OF INFECTION, 2013, 67 (06) :606-616

[27] Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset [J].

Chan, Jasper Fuk-Woo ;

Yao, Yanfeng ;

Yeung, Man-Lung ;

Deng, Wei ;

Bao, Linlin ;

Jia, Lilong ;

Li, Fengdi ;

Xiao, Chong ;

Gao, Hong ;

Yu, Pin ;

Cai, Jian-Piao ;

Chu, Hin ;

Zhou, Jie ;

Chen, Honglin ;

Qin, Chuan ;

Yuen, Kwok-Yung .

JOURNAL OF INFECTIOUS DISEASES, 2015, 212 (12) :1904-1913

[28] Massively parallel de novo protein design for targeted therapeutics [J].

Chevalier, Aaron ;

Silva, Daniel-Adriano ;

Rocklin, Gabriel J. ;

Hicks, Derrick R. ;

Vergara, Renan ;

Murapa, Patience ;

Bernard, Steffen M. ;

Zhang, Lu ;

Lam, Kwok-Ho ;

Yao, Guorui ;

Bahl, Christopher D. ;

Miyashita, Shin-Ichiro ;

Goreshnik, Inna ;

Fuller, James T. ;

Koday, Merika T. ;

Jenkins, Cody M. ;

Colvin, Tom ;

Carter, Lauren ;

Bohn, Alan ;

Bryan, Cassie M. ;

Alejandro Fernandez-Velasco, D. ;

Stewart, Lance ;

Dong, Min ;

Huang, Xuhui ;

Jin, Rongsheng ;

Wilson, Ian A. ;

Fuller, Deborah H. ;

Baker, David .

NATURE, 2017, 550 (7674) :74-+

[29] Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [J].

Chu, CM ;

Cheng, VCC ;

Hung, IFN ;

Wong, MML ;

Chan, KH ;

Chan, KS ;

Kao, RYT ;

Poon, LLM ;

Wong, CLP ;

Guan, Y ;

Peiris, JSM ;

Yuen, KY .

THORAX, 2004, 59 (03) :252-256

[30]

Coates M, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00737-17, 10.1128/aac.00737-17]

← 1 2 3 4 5 6 7 8 9 10 →